F-PSA to total PSA (i.e. F-PSA + PSA-ACT) has been shown to improve the diagnostic sensitivity and specificity for prostate cancer compared with determination of total PSA alone . Specific determination of PSA-ACT has also been reported to increase the sensitivity and specificity for prostate cancer (Stenman et al, 1991; Leinonen et al, 1993) .
This paper describes the establishment of MAb against PSA, characterization of the antigenic domains of PSA using the established MAb and development of immunoassays for specific determination of different serological forms of PSA.
MATERIALS AND METHODS
Purification of PSA, PSA-ACT and PSA-a2M complex PSA was purified from pooled seminal plasma from healthy volunteers by ion-exchange chromatography and gel chromatography, essentially as described (Christensson et al, 1990) . Homogeneity of the purified PSA was tested by SDS-PAGE of unreduced PSA on 10% homogeneous gels stained with Comassie brilliant blue. The complex between PSA and ACT (Biodesign, MD, USA) was obtained by incubation of purified PSA and ACT (Christensson et al, 1990) and purification by size exclusion chromatography on Sephacryl S-100 (Pharmacia LKB Biotechnology, Sweden) eluted with phosphate-buffered saline (PBS) pH 7.1. The elution was monitored by determination of PSA immunoactivity in the eluted fractions using PSA Delfia kit (Wallac Oy, Turku, Finland) . Peak fractions corresponding to a molecular size of approximately 100 kDa and approximately 30 kDa were pooled and concentrated by ultra filtration in an Amicon UF cell and YMIO filter (Amicon, MA, USA). The PSA-ax2M complex was formed by incubation of human a2M (Biodesign, MD, USA) with twofold molar excess of PSA for 4 h at 37°C and used without further purification. The concentration of the PSA-a2M complex was estimated by calculation of the PSA concentration before and after incubation with a2M. The 'PSA-cx2M fraction' was estimated to contain 8 jg 1-1 F-PSA and approximately 34 jig 1-' PSA-a2M, i.e. the fraction contained 42 jig 1-1 PSA before incubation with ct2M and 8 ,ug 1-' PSA after incubation; thus the concentration of PSA-o2M was estimated to be = 34 jig 1-1 (with respect to PSA content).
Establishment of anti-PSA MAb
Female Balb/c mice, 5-6 weeks of age, were immunized i.p. with approximately 10 jig of purified PSA in Ribi Adjuvant System (Ribi ImmunoChem Res., MT, USA). The mice received four to five booster doses with 5-10 jig of PSA-ACT in Ribi adjuvant over 50-100 days. Three to five days after the final booster dose, hybridomas were obtained by fusion of spleen cells with the Ag8 myeloma cell line (ATCC, Rockville, MD, USA) (Lindholm et al, 1983) . The hybridomas were screened by incubation of hybridoma medium in microtitre plates (Nunc, Denmark) coated with affinity purified goat anti-mouse IgG+M (Jackson Immunoresearch Laboratory, PA, USA); incubation of antibody-coated microtitre plates with 100 jil of PSA (100 jig 1-') overnight; and detection of positive clones by incubation with polyclonal rabbit anti-human PSA Ig and HRP swine anti-rabbit Ig (Dako AS, Denmark). Positive clones were further screened with purified PSA-ACT complex. The selected hybridomas were cloned twice by limiting dilution; monoclonal antibodies were produced by in vitro cultivation in DMEM (Gibco, UK) containing 5% fetal calf serum (HyClone Laboratories, UT, USA) and purified by ProSep protein A affinity chromatography, according to the manufacturer's instructions (BioProcessing, UK). The isotype of the monoclonal antibodies was determined in a solid-phase ELISA with goat antimouse Ig (G+A+M) as catching antibody and peroxidase-labelled isotype-specific rabbit anti-mouse IgGI, IgG2a, IgG2b, IgG3, IgA and IgM as detecting reagents (Zymed Laboratories, CA, USA).
Determination of epitope specificity
The specificity of the hybridomas was analysed by determination of the reactivity with purified PSA, PSA-ACT and ACT in ELISA assays, competitive binding inhibition studies, dose-response curves of different MAb combinations and Western blot of reduced and unreduced PSA and of unreduced PSA-x2M separated by SDS-PAGE. The epitope specificity of the MAbs was further characterized by determination of their potential to inhibit the PSA enzyme activity against a low molecular peptide substrate.
ELISAs
Anti-PSA MAb solid phase was obtained by incubation of each purified anti-PSA MAb (5g ml-') in 0.2 M sodium dihydrogen phosphate overnight at 22-24°C in Nunc MaxiSorp C12 or C8 immunomodule plates (Nunc, Denmark); after washing, nonspecific binding was blocked by incubation with 6% sorbitol, 0.5% bovine serum albumin (BSA) in Tris-buffered saline (TBS) (pH 7.75).
The gross specificity of the MAbs was determined by incubation of 25,u1 of serial dilution of purified PSA, PSA-ACT or ACT (500-0 jig 1-1 with the addition of 100 jil of incubation buffer (lOg 1-' BSA, 0.5 g 1-' bovine Ig and 0.1 g l-' Tween 20 in TBS pH 7.75) in duplicates for 1 h in the anti-PSA MAb-coated microtitre plates (MTPs); after washing, the wells were incubated with polyclonal rabbit anti-human PSA Ig (or polyclonal rabbit anti-human ACT Ig when ACT was used as antigen), and absorbance was determined at 450 nm after incubation with HRP swine anti-rabbit Ig and orthophenyl diamine (OPD) substrate.
Competitive binding-inhibition assays
The anti-PSA MAbs were labelled with N1-DTTA europium (Eu) chelate (Wallac Oy, Turku, Finland) to specific activities of 4-7 Eu/IgG as previously described (Hemmila et al, 1983) . The competitive binding-inhibition assays were performed as follows: 100 jl of PSA (100 jig 1-1) was incubated for 1 h in the anti-PSA MAb-coated MTP; after washing, 25 jl of unlabelled anti-PSA MAb plus 100 jl Eu Anti-PSA MAb (1 jg ml-') were added in triplicate and incubated for 1 h. The Eu fluorescence was determined in an Arcus 1230 fluorometer after addition of 200 jil Enhancement Solution. The inhibition was calculated as per cent decrease in signal in the presence of unlabelled anti-PSA MAb compared with the signal without unlabelled anti-PSA MAb. The inhibition assays were performed in two steps; firstly, 'screening' with the concentration of inhibitor constant at S jig ml' and, secondly, determination of inhibition curves using 100-0.16 jg ml' of inhibiting MAb. The inhibition studies were performed with the hybridomas reacting with F-PSA and F-PSA + PSA-ACT.
MAbs giving total cross-inhibition with each other (i.e. the same antibody combination giving >80% inhibition both as inhibiting and labelled MAb) were included into the same antibody group. Differences in dose-response, inhibition with different MAb combinations and reactivity in Western blot were used as criteria for separation of the MAbs into subgroups.
Inhibition of polyclonal Anti-human PSA Ig.
The inhibition of the binding of a polyclonal rabbit anti-PSA antiserum to solid-phase immobilized PSA by the anti-PSA MAbs was tested in a similar competitive binding-inhibition assay as described above. PSA was incubated in the anti-PSA MAb-coated MTP, and 100 jil of the Anti-PSA MAbs (10 jig ml-') was added in triplicate; after 30 min incubation, 100 jil of polyclonal rabbit antihuman-PSA Ig (Dako AS) diluted 1:500 was added, and the incubation continued for another 30 min; after washing, HRP-swine anti-rabbit Ig was added and incubated for 30 min. The inhibition was tested with individual anti-PSA MAb and different combinations of the anti-PSA MAb, but the final concentration of inhibiting MAb was kept constant at 10 jg ml' in all experiments.
Inhibition of PSA enzyme activity with anti-PSA MAb
The effect on the PSA proteolytic activity was studied by inhibition by anti-PSA MAb of the hydrolysis of the chromogenic peptide substrate S-2586 (MeO-Suc-Arg-Pro-Tyr-pNA), Chromogenix AB, Molndal, Sweden. The hydrolysis of S-2586 peptide by PSA was performed essentially as described by Christensson et al (1990) but was adapted to be performed in microtitre plates. In the assay, 2.5-5 jig of purified PSA (or seminal plasma corresponding to 2.5-5 jig PSA) in 100 jil of 50 mm Tris-HCI, 0. IM sodium chloride pH 7.8, was incubated together with 0.01-75 jig of anti-PSA MAb for 30 min, and then 3-10 mm S-2586 substrate was added and the hydrolysis was determined at room temperature during a British Journal of Cancer (1997) 75(6), [789] [790] [791] [792] [793] [794] [795] [796] [797] Epitope mapping of PSA 791 period of 20 min. In control experiments, the hydrolysis was tested by incubation of S-2586 in (a) buffer without PSA or anti-PSA MAb and (b) buffer with anti-PSA MAb without PSA. The hydrolysis of the S-2586 substrate was determined at 405 nm every 30s for 20 min in a Molecular Device vMax microtitre plate reader. The inhibition of the hydrolysis by the anti-PSA MAb was calculated as the difference in Abs4O5nm between 0 and 20 min with and without addition of anti-PSA MAb.
Dose-response and specificity of different anti-PSA MAb combinations Dose-response curves were determined for all combinations of the anti-PSA MAb as follows: 25 pl of antigen (500, 100, 10, 5, 1 and 0 ng ml-F-PSA, PSA-ACT or ACT) plus 100 gl of incubation buffer was incubated in duplicates for 30-60 min in microtitre plates coated with anti-PSA MAb; after washing, 100 pl of Eu anti-PSA MAb (1 jg ml-') was added, and the incubation was continued for an additional 30-60 min. The Eu fluorescence was determined in an Arcus flurorometer after additional washings and incubation with 200 pl Enhancement Solution.
The antigen specificity of the different MAb combinations was confirmed by determination of dose-response curves with purified F-PSA, PSA-ACT and ACT and by determination of the PSA immunoactivity in eluted fractions from S-100 gel chromatography of a mixture of F-PSA and PSA-ACT complex. The preliminary clinical specificity of the different assays was compared with PSA Delfia kit in samples from subjects with benign prostate hyperplasia and prostate cancer.
The relative response for F-PSA and PSA-ACT of different total PSA assays was analysed essentially as described previously (Lilja et al, 1991 ) -a control sample with seminal plasma containing 100 ,ug of PSA in 2 ml PBS (pH 7.2), and a test sample containing seminal plasma, 100 jg of PSA and 500 jig of ACT in 2 ml PBS (pH 7.2) was incubated for 2 h at 37'C. Thereafter the two samples were analysed in quadruplicate in the respective assay after dilution 1:200 with incubation buffer.
SDS-PAGE and western blot
The binding of the antibodies to reduced and non-reduced PSA was analysed by Western blot analysis after SDS-PAGE. Purified PSA was reduced with mercaptoethanol as follows: PSA was mixed in a ratio of 1:1 (v/v) with sample buffer (50 mM Tris HCl (pH 6.8) containing 0.2% mercaptoethanol, 15% glycerol, 5% pyronin Y and 3% SDS) and incubated for 5 min in a boiling water bath. For analysis of non-reduced PSA mercaptoethanol was omitted from the sample buffer. After denaturation (± reduction) the sample, 2 jig of PSA per lane, was immediately separated on homogeneous 10% polyacrylamide gels in A Bio-Rad Protean II electrophoresis cell (Bio-Rad Laboratories, CA, USA) at 25-35 mA per gel using 20 mM Tris pH 8.3, 14 g 1-' glycine, 1 g 1-1 sodium dodecyl sulphate (SDS) as electrophoresis buffer. The reactivity with PSA-a2M was tested by SDS-PAGE of unreduced denaturated PSA-a2M on a 5-15% gradient polyacrylamide gel. After electrophoresis, the samples were electroblotted onto BA85 nitrocellulose membrane (Schleicher & Schull, Germany) using a Trans-Blot Cell (Bio Rad Laboratories, CA, USA). The NC membrane was blocked for 2 h in 3% TBS-BSA, washed twice for 10 min in tris buffered saline containing Tween 20 (TTBS), cut into strips and incubated with the anti-PSA MAb (5 jig ml-') in TBS-BSA for 2 h; after three 10-min washes in TTBS, the strips were incubated with HRP rabbit anti-mouse Ig for 1 h and visualized using 4-chloronaphthol (Bio-Rad Laboratories, CA, USA).
RESULTS
In total, 33 different hybridomas were selected because of the apparent high affinity and used for production of MAb. All but one (IgG2a) produced MAb of the IgGI isotype.
ELISA against purified PSA, PSA-ACT and ACT Based on the reactivity with F-PSA, PSA-ACT and ACT, the hybridomas were divided into three major groups: group A, 17 Table 1 Antigenic domains recognized by anti-PSA MAb Group A: epitopes exposed in both free PSA and PSA-ACT complex
Group B: epitopes exposed only in free PSA Group C: epitopes exposed in ACT   I  II   a   b   PSA6  PSA17  PSA25  PSA55  PSA57  PSA30  PSA19  PSA63  PSA60  PSA20  PSA53  PSA68  PSA61  PSA70  PSA64 PSA75
The Anti-PSA Mabs were established and the specificity determined as described in Materials and methods.
British Journal of Cancer (1997) (Figure iB) and the dose-response curves using PSA17, PSA19 or PSA20 as solid-phase or tracer MAbs in sandwich immunoassays ( Figure IC ) indicated that the antibodies should be separated into two subgroups: group AMa consisting of PSA8, PSA13 and PSA31 and group AIb PSAO0, PSA33 and PSA69.
The PSA66, PSA67 and PSA71 MAbs showed a cross-inhibition of > 80% and were included as group All (data not shown). Based on the differences in inhibition pattern with MAbs of group AIII (data not shown) and reactivity with reduced PSA (see Figure  3) , the PSA66 and PSA7 1 MAbs were included in group Alla, and PSA67 MAb was included in group AlIb.
The PSA29, PSA36 and PSA45 MAbs inhibited each other > 80% and were included as group AIII. These MAbs were also British Journal of Cancer (1997) 75(6) The group B MAbs cross-inhibited each other by more than 80% ( Figure 2B3 ). They were also inhibited =80% by group V and VI, and a partial inhibition was also seen with group Ala MAb and group Allla MAb (Fig 2A) Figure 4 MAbs of the different groups were mixed (total concentration 10 gg ml-1), and the inhibition was performed as described in Material and methods. In the figure, the mean + s. (Figure 3 ). All PSA MAbs reacted with PSA-o2M in Western blot after SDS-PAGE, and there were no obvious differences between group A and group B MAbs in the recognition of PSA-a2M after SDS-PAGE Western analysis (data not shown).
Design of sensitive equimolar-response assays for determination of total-PSA Sandwich assays with an apparent equimolar response for F-PSA and PSA-ACT were designed using MAbs of Group AIb, Alla, AIII, AV and AVII. In particular, sandwich assays using PSAlO, PSA29, PSA36, PSA66 and PSA42 MAbs resulted in Delfia assays with high sensitivity (lower limit of detection (LLD) << 0.01 ,ug 1-1 using 25 ,ul of sample (LLD defined as the concentration corresponding to the signal of 2 x s.d. of six-replicate determination of the zero standard) and fast kinetics (30 + 30 min). The prototype assays showed a good correlation with commercial assays for determination of PSA -coefficient of correlation > 0.98 compared with PSA Delfia in 70 samples from subjects with BPH and prostate cancer (data not shown).
The relative response in the sample with PSA and ACT incubated for 2 h at 370C were 99 ± 3% (mean ± s.d.) of the response of the control sample for the assays PSA1O-PSA66, PSA1O-PSA36, PSA66-PSA36 and PSA66-PSA42 using 25 g1 of sample and 30 + 30 min incubation time. The PSA42-PSA29 assay showed a relative response of 84 ± 3% using 30 + 30 min incubation and 97 + 2% using 1 + 1 h incubation ( Table 2) .
Design of assays for determination of F-PSA
The MAbs of Group B could not be combined with each other in sandwich assays. However, combination of MAbs of Group B and Group A resulted in assays specific for F-PSA. In particular, combination of the Group B MAbs either as catching MAb or as detecting MAb together with MAb PSA66 of Group AIla or PSA 36 MAb of Group AIIIb resulted in assays with high sensitivity. The specificity of these assays, i.e. cross-reaction between F-PSA and PSA-ACT, was << 1% determined either by response of purified PSA-ACT complex or determination of response in eluted fractions corresponding to PSA-ACT after separation of F-PSA and PSA-ACT by size exclusion chromatography on Sephacryl S-100. The immunoassays using PSA42 and/or PSA54 either as catching or detecting antibody in combination with the Group B Mabs did not give any dose-response curves, and a poor dose-response relationship was also seen with antibodies of group Ala and AllIa. This is in agreement with the fact that the PSA 42 Assays for determination of PSA-ACT Using antibodies from Group A as catching MAbs and MAbs from group C as detecting MAbs, it was possible to design two-step sandwich assays for specific determination of the PSA-ACT complex without (<< 1%) cross-reactivity with F-PSA (data not shown).
DISCUSSION
The existence of different molecular forms of PSA in serum and significant differences in the proportions of the serological forms of PSA between individuals (Lilja et al, 1991; Stenman et al, 1991; Christensson et al, 1993) and between benign and malignant prostate disease has further increased the importance of well-characterized immunological reagents for standardization of PSA immunoassays (Graves et al, 1990; Graves, 1993; Stamey et al, 1994) and for development of assays for specific determination of different forms of PSA. In this paper, antigenic domains of PSA were characterized in order to find optimal pairs of MAbs to be used in immunoassays for determination of F-PSA and total PSA (i.e. F-PSA+PSA-ACT complex).
The epitope mapping indicated a complex pattern of eight to nine unrelated and partly overlapping antigenic domains in PSA. The complexity of the antigenic domains was further increased by the existence of several epitopes within each domain (e.g. see separation of Group Al into at least two subgroups, Figure lA-C) . In order to illustrate the possible relationship between the different antigenic domains, a hypothetical 'map' of the antigenic domains Figure 5 The group A MAb recognized epitopes exposed both in F-PSA and PSA-ACT, while the group B MAb recognized epitopes that were covered by the ACT and only exposed in F-PSA. The figure gives an illustration of the possible relation between the different domains recognized by the established MAbs of PSA was drawn ( Figure 5) . In our study, mixing MAbs of different groups resulted in a step-wise increased inhibition of a polyclonal rabbit anti-PSA antiserum, which clearly indicated that antibodies of the different groups recognized different antigenic domains in PSA. The initial screening procedure used in this study with unlabelled PSA in solution may have exposed epitopes not exposed in PSA-coated on solid phases or in labelled PSA, which may explain the large number of different antigenic domains detected in this study compared with previous studies. All studies indicate a surprisingly complex epitope map of PSA, and further characterization of the reactivity with hKI, hK2 and different recombinant forms of PSA would be needed in order to define true PSAspecific antigenic domains. Reduction of the five intra-chain S-S bonds in PSA and denaturation with SDS will completely destroy the native three-dimensional structure and also separate PSA into intact PSA and 'nicked' forms of PSA (i.e. PSA with internal cleavage of the amino acid sequence which in the native form is held together by the intra-chain S-S bonds). In this study, Western blot analysis of reduced and non-reduced PSA by SDS-PAGE was used to separate antibodies whose recognition of PSA was dependent only on the linear sequence of amino acids (i.e. true continuous epitopes) and those that were dependent on the three-dimensional structure of PSA. Non-reduced PSA was recognized in the Western blot analysis after SDS-PAGE by all MAbs, but there were clear differences in reactivity with reduced PSA between the MAbs. Reactivity with reduced PSA strongly suggested that the epitopes consisted of linear sequences of amino acids. The AIII MAbs (and polyclonal antibody anti-PSA) reacted also with fragments of PSA indicating that these antibodies also recognized 'nicked' forms of PSA. Those MAbs that only recognized non-reduced PSA may recognize discontinuous epitopes dependent on the three-dimensional structure of the PSA molecule for binding, but it is not possible to exclude the existence of continuous epitopes also within this group. Although both reduced and non-reduced PSA was recognized by some of the anti-PSA MAb, the reactivity was clearly lower with the reduced form of PSA. Thus, the native conformation of the PSA molecule was of major importance for the binding to PSA of all MAbs.
The reaction between PSA and cx2-macroglobulin leads to total encapsulation of the PSA molecule, and the PSA-a 2M complex is not detected in conventional immunoassays. Denaturation of the PSA-x2M complex with SDS leads to the formation of two subunits with an approximate molecular weight of 380 kDa and exposure of the PSA moiety; and PSA-a2M has been detected in human serum using SDS-PAGE (Zhou et al, 1993) . Interestingly, there was no difference in the recognition of PSA-ac2M in SDS-PAGE between MAbs recognizing epitopes exposed both in F-PSA and PSA-ACT and the MAbs recognizing epitopes exposed only in F-PSA.
The proteolytic activity of PSA against the S-2586 substrate was almost completely inhibited by most antibodies, and only the antibodies PSA66, PSA71, PSA67, PSA45 and PSA36 inhibited the proteolysis by less than 50%. It was expected that the antibodies recognizing epitopes specific for F-PSA would inhibit the proteolytic activity of PSA, but it was expected less that most antibodies against exposed epitopes inhibited the enzymatic activity of PSA. The results suggested that binding of anti-PSA MAb to PSA induced conformational changes leading to loss of enzymatic activity of PSA.
At present, there are three areas of main interest related to the design of PSA immunoassays: ultrasensitivity, equimolar response assays (i.e. assays with the same molar response for F-PSA and PSA-ACT) and assays for specific determination of the different serological forms of PSA. The novel luminometric and fluorometric detection methods and high-affinity antibodies make a further clinical studies (Vessella, 1993; Vessella and Lange 1993; Yu and Diamanidis, 1993; Prestigiacomo and Stamey, 1994) . The detailed specificity of the immunoreagents is of great importance for determination of PSA in the ultrasensitive range to exclude determination of other members of the kallikrein gene family. The terms equimolar and skewed-response assays have been introduced to describe the differences in molar response between F-PSA and PSA-ACT of immunoassays (Graves 1993) . Differences in the molar response for F-PSA and PSA-ACT may partly explain the discordant results between assays based on monoclonal antibodies (mono-mono assays), polyclonal antibodies (poly-poly assays) or assays using both mono-and polyclonal antibodies (mono-poly assays). In poly-poly or mono-poly assays, non-equimolar response may be obtained because additional epitopes are available for the polyclonal antibodies in F-PSA compared with PSA-ACT thus leading to an overestimation of the F-PSA fraction. However, the problem of non-equimolar response is also evident in mono-mono assays, and diagnostic kits using mono-mono design with large differences in molar response between F-PSA and PSA-ACT are available. Reports have suggested that poly-mono assays may reflect the clinical course of prostate cancer more accurately than mono-mono assays (Bluestein et al, 1992) and may also be less sensitive towards interference from heterophilic antibodies than mono-mono assays (Slota et al, 1994) . Thus, the proper choice of monoclonal antibodies is of major importance for the design of immunoassays giving equimolar response for F-PSA and PSA-ACT and maximum recognition of the different forms of PSA in serum.
The combination of the MAbs of Group A resulted in several sandwich assays with similar molar response for F-PSA and PSA-ACT. In particular the combination of MAbs of Group AIb, All, AIII and AV resulted in highly sensitive assays (LLD < < 0.01 ig 1-1 using 25 gl of sample) for determination of total PSA (i.e. F-PSA + PSA-ACT). The sandwich assays using PSA1O-PSA66, PSA1O-PSA36, PSA66-PSA36 and PSA66-PSA42 MAbs gave an equal response to the control sample containing only F-PSA and the test sample containing = 60% F-PSA and = 40% PSA-ACT, suggesting an equimolar response for F-PSA and PSA-ACT of these assays. The equimolarity of the assays were also supported by the identical dose-response and kinetics of purified F-PSA and PSA-ACT. The combination of PSA42-PSA29 showed a lower relative response in the test sample using 30 + 30 min incubation, suggesting a non-equimolar response using this assay configuration, while 60 + 60 min incubation showed almost the same response as in the control sample. Further studies indicated that the nonequimolar response of the PSA42-PSA29 assay was as a result of the use of PSA42 MAb as catching MAb. Thus, the proper choice of immunoreagents, orientation of the antibodies as well as the general assay design will influence the molar response between F-PSA and PSA-ACT of different mono-mono sandwich PSA assays.
The initial findings of lower proportions of F-PSA in prostate cancer than in BPH (Stenman et al, 1991; Christensson et al, 1993) and the improved discrimination between BPH and prostate cancer by determination of the ratio between F-PSA and total PSA or PSA-ACT has focused interest on immunoassays specific for F-PSA and/or PSA-ACT. In order to obtain optimal specificity of the F-PSA-total PSA ratio, it is essential that the assays used for determination of F-PSA show minimal cross-reactivity between F-PSA and PSA-ACT and that the total PSA assay gives an equimolar response for F-PSA and PSA-ACT. The F-PSA specific antibodies recognized the same or very similar antigenic domain and could thus not be combined in sandwich assays. To our knowledge, there are no F-PSA-specific antibodies available that can be combined in sandwich pairs, suggesting that the F-PSA-specific antigenic domain is relatively restricted. The combination of the F-PSA specific MAbs and MAbs of Group Alla or AIIIb resulted in highly sensitive and specific assays for determination of F-PSA. The cross-reactivity of the preferred configurations was clearly < 1% (0.1-0.2%) suggesting that these assays would be suitable for further clinical evaluation of determination of F-PSA. Enzyme immunoassays for specific determination of F-PSA and total PSA have been developed using the PSA30, PSAlO and PSA66 MAbs (Nilsson et al, 1994) and used for determination of F-PSA and the ratio between F-PSA and total PSA in BPH, prostate cancer and healthy individuals (Nilsson et al, 1994a) .
The MAb directed against the ACT portion of the PSA-ACT complex could be used as detecting MAb together with the catching MAb of group A for the development of sensitive and specific sequential sandwich assays for determination of PSA-ACT. Determination of the ratio between F-PSA and PSA-ACT instead of F-PSA-T-PSA ratio would theoretically further improve the discrimination between BPH and CAP. However, assays using anti-ACT antibodies as tracer may show severe background problems because of non-specific adsorption of cathepsin G and/or ACT to plastic surfaces, resulting in binding of the anti-ACT tracer; this has limited the practical usefulness of this assay design for specific determination of PSA-ACT (Leinonen et al, 1993) . Therefore, our approach for the development of PSA-ACT-specific assays is to try to establish MAbs specific for the PSA-ACT complex without reactivity with active ACT and to use these antibodies for development of PSA-ACT-specific assays which should not give problems related to unspecific adsorption of an anti-ACT tracer.
At present, there are independent studies using different immunological reagents and patient materials (Nilsson et al, 1994b; Wang et al, 1994; Prestigiacomo and Stamey, 1995) which have confirmed the initial finding that specific determination of different serological forms of PSA may significantly improve the discrimination between benign and malignant prostate disease (Stenman et al, 1991; Christensson et al, 1993) . However, the exact molecular differences and a biological explanation for the difference in PSA between BPH and prostate cancer has so far not been elucidated. Carefully characterized monoclonal antibodies directed against different antigenic domains of PSA may be useful not only for development of immunoassays for determination of different serological forms of PSA but also for the further immunological characterization of the different forms of PSA. The 'F-PSA' fraction may be heterogeneous containing different forms of enzymatically inactive PSA. Preliminary studies have suggested differences in the proteolytic activity of PSA in serum from healthy individuals and BPH compared with subjects with prostate cancer (Paus et al, 1995) ; this could explain the different proportions of F-PSA between BPH and CAP. The detailed biochemical and immunological characterization of PSA and/or PSA-related substances will be needed to further clarify the 'true' biochemical and molecular nature of the different serological forms of PSA.
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